The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer

Lung Cancer. 2010 Sep;69(3):365-6. doi: 10.1016/j.lungcan.2010.06.017.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anemia / etiology
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Blood Cell Count
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / physiopathology
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Clinical Protocols
  • Female
  • Humans
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Lung Neoplasms / physiopathology
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Neutropenia / etiology
  • Vinblastine / administration & dosage
  • Vinblastine / adverse effects
  • Vinblastine / analogs & derivatives
  • Vinorelbine

Substances

  • Vinblastine
  • Cisplatin
  • Vinorelbine